Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline

Danaher beat Q2 estimates and raised its 2025 earnings guidance as bioprocessing strength and cost control boosted profit margins and revenue.

Latest Ratings for DHR

DateFirmActionFromTo Jan 2022Wells FargoMaintainsOverweight Jan 2022BarclaysMaintainsOverweight Jan 2022BernsteinInitiates Coverage OnOutperform

View More Analyst Ratings for DHR

View the Latest Analyst Ratings

read more